KalVista Pharma Appoints New CMO, Director
Ticker: KALV · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $42,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-appointment, executive-appointment
Related Tickers: KALV
TL;DR
KalVista just hired a new CMO and added a director to the board. Big changes coming?
AI Summary
KalVista Pharmaceuticals, Inc. announced on November 23, 2024, the appointment of Dr. Andrew Sinclair as Chief Medical Officer and the election of Ms. Sarah Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its officers. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
Changes in key leadership roles like Chief Medical Officer and Board of Directors can signal shifts in company strategy, research direction, and governance.
Risk Assessment
Risk Level: medium — Changes in executive and board leadership can introduce uncertainty and potential shifts in strategic direction, impacting the company's future performance.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- Dr. Andrew Sinclair (person) — Appointed Chief Medical Officer
- Ms. Sarah Kelly (person) — Elected to Board of Directors
- November 23, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Andrew Sinclair has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Sarah Kelly has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is November 23, 2024.
What type of SEC filing is this?
This is a Current Report (Form 8-K) filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What other information is disclosed regarding officers?
The filing also discloses compensatory arrangements of certain officers.
Filing Stats: 761 words · 3 min read · ~3 pages · Grade level 10.9 · Accepted 2024-11-26 07:06:01
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
- $42,500 — common stock (ii) an annual retainer of $42,500 paid in cash and (iii) an annual award
Filing Documents
- d851354d8k.htm (8-K) — 27KB
- d851354dex991.htm (EX-99.1) — 9KB
- 0001193125-24-265612.txt ( ) — 160KB
- kalv-20241123.xsd (EX-101.SCH) — 3KB
- kalv-20241123_lab.xml (EX-101.LAB) — 18KB
- kalv-20241123_pre.xml (EX-101.PRE) — 11KB
- d851354d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: November 26, 2024 By: /s/ Brian Piekos Brian Piekos Chief Financial Officer